BRTX vs CVS · rev $401.0K vs P/E 16, rev $402.07B
BioRestorative Therapies Inc (BRTX) versus CVS Health Corp (CVS) — a side-by-side from cached financials, not a winner call.
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
BRTX currently screens at market cap $10.2M. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Not investment advice. Open the BRTX and CVS stock pages for the full models.
Not investment advice.